Biocept reports second quarter 2023 financial results

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended june 30, 2023 and provides a business update. “biocept's primary focus is establishing our proprietary cerebrospinal fluid assay cnside™ as standard of care. we continue to diligently work towards submission to the national comprehensive cancer network® (nccn®) for consideration to include cnside in their.
BIOC Ratings Summary
BIOC Quant Ranking